Shenzhen Neptunus Bioengineering (000078) Stock Overview

Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine tablets, chlorpheniramine maleate tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and provides value-added services for hospitals, medical institutions, and drug retail institutions and distributors. The company offers drugs in the fields of malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, and multiple diseases, such as respiratory system and digestive system. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 1989 and is headquartered in Shenzhen, China.